User blogs

Tag search results for: "parents rights"

Parents who want alternatives to mental health drugs, suggested by teachers, mental health professionals, doctors or ex-spouses, may be relieved to know that there is a medical test that can be performed to evidence whether your child can even metabolize the drug that is being proposed.

 

This test has been around for a long while, yet the medical community has not used it nor made it broadly known as it may cut into pharma spending. The test is a genomic test, meaning it tests the DNA function and structure and through this, can determine if the individual can break down the drug and move it through the body or will the liver become overwhelmed and the individual become toxic, and therefore experience the adverse effects of the mental health drugs, such as psychosis, worsening depression, anxiety, mania, delusions, suicidal thoughts, homicidal thoughts and more.

 

Like all things in our culture and in our society that revolves around money, the test is currently being used and promoted for use to the psychiatric community.  Now, if the use of it were as healthful as what has been suggested above, in order to test the individual to see if they will be able to metabolize the drug, therefore they would most definitely be wise to learn of the alternative, non pharmaceutical treatment, then we would live in an ideal world. Yet, that is not the intention, nor the purpose for promoting this test to the psychiatric community.  Mental health professionals are using the test in order to find the drug that rates “best” in their estimation. (Please refer to the FDA warnings on mental health drugs to understand the risks they carry, www.fda.gov). Mental Health drugs cannot rate "best" in any estimation.

 

In a highly scientific article regarding this genomic testing, the facts relayed are as follows.  “drug-metabolizing enzyme genes, such as cytochrome P 4 5 0 2D6 gene (CYPD6), were identified.” That’s the good news.  The genes that partake in metabolizing drugs were identified through genomic research.

 

The article continues, with the benefit of this news as it “provides clinicians with the opportunity to identify both poor metabolizers and ultrarapid metabolizers…”

 

The article does point out that “In recent years, the potential iatrogenic harm (illness caused by the drug) associated with psychotropic medications has become increasingly obvious, with “black-box warnings” being attached to antidepressants, antipsychotic medications, stimulants, and mood stabilizers.”

 

Again, this is not necessarily new technology, this is new to the public, “The identification of specific gene variants associated with idiosyncratic responses is about 50 years old, and the recognition that some psychiatric patients metabolize antidepressants at dramatically different rates has been documented for several decades.”

 

Some information for those parents who want to approach their doctors to do this testing and assert their right to alternative treatment for their child:

 

“CYP2D6 was the first drug-metabolizing enzyme gene that was genotyped to identify psychiatric patients with increased or decreased metabolic capacity.  It is located on chromosome 22 and consists of 4382 nucloetides…

 

The CYP2DC enzyme plays a primary role in the metabolism of more than 70 substrate medications, including twelve psychotropic medications…

 

The most important CYP2D6 phenotype to identify is the poor 2D6 sustrate metabolizer phenotype. Patients who are poor metabolizers are at increased risk of adverse events when they are prescribed 2D^ substrate medications, because of their low metabolic capacity.”

 

 

For more factual information that helps to get you fully informed on your rights in the field of mental health, visit www.mentalhealthrights.org

 

 

 

Source:

 

Psychiatric pharmacogenomics testing in clinical practice, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181940/